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1. Introduction 
1.1 Vessel growth and angiogenesis 
The process that involves vessel formation and growth has been described by the terms 
vasculogenesis and angiogenesis, as two distinct types [Demir et al., 2007]. Both of these 
processes are essential for normal uteroplacental development: 
a. vasculogenesis, meaning new blood vessel formation from hemangiogenic stem cells 
(derived from mesenchymal cells) that differentiate to hemangioblastic stem cells, 
essentially occurring during fetal development. Vasculogenesis consists of three major 
steps: i. induction of hemangioblasts and angioblasts -mediated mainly through 
fibroblast growth factor (FGF), ii. assembly of primordial vessels -mediated mainly by 
vascular endothelial growth factor/vascular endothelial growth factor receptor system 
(VEGF/VEGFR) iii. transition from vasculogenesis to angiogenesis [Flamme et al., 
1997]; 
b. angiogenesis, meaning new branches from pre-existing vessels, which is occurring in 
the female reproductive tract during the formation of the corpus luteum, during 
endometrial development and during embryo implantation and placentation. Two 
forms of angiogenesis have been described: sprouting and non-sprouting angiogenesis 
(intussusception) [Folkman et al., 1992]. The process of angiogenesis has three phases: 
initiation, proliferation-invasion and maturation-differentiation. 
The vascularisation of placental villi starts at day 21 post conception (dpc), being the result 
of local de novo formation of capillaries rather than protrusion of embryonic vessels into the 
placenta [Demir et al., 1989]. Mesenchymal cells inside the villi transform into 
hemangiogenic precursor cells that migrate toward the periphery. In the latter, prior to the 
formation of the first vessels that are observed by about 28 dpc (erythrocytes are detected by 
32 dpc), mesenchymal derived macrophages (Hofbauer cells) appear. Those macrophages 
will express angiogenic growth factors and, as they appear early, they suggest a paracrine 
role in the initiation of vasculogenesis. Angiogenic growth factors are also expressed by the 
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maternal decidua and macrophages mediating the trohpoblast invasion [Ahmed et al., 
1995]. In the meanwhile since the uterus and its contents demand an increased supply of 
blood during pregnancy, its vasculature undergoes three main adaptative changes: 
vasodilation, increased permeability, and growth and development of new vessels. So the 
villi mature and angiogenesis begins at around 32 dpc [Zygmunt et al., 2003]. 
Branching or sprouting angiogenesis (lateral ramification of pre-existing tubes) is first 
observed leading to the formation of a capillary network. During branching angiogenesis 
multistep processes are taking place including increased vascular permeability, degradation 
of basement membrane, increase in endothelial cell proliferation and migration, formation 
of endothelial cell tubes, and recruitment of pericytes to the outside of the capillary to form 
a stable vessel [Kaufmann et al., 2004]. From the 6th week a basal lamina begins to form 
around the capillaries that results to a web like arrangement of capillaries within the stroma 
of mesenchymal villi, and a superficially location of most of the capillaries in the immature 
intermediate villi (beneath the trophoblast, covering the villous surface). In the latter, from 
the 15th week onwards, fibrosal stromal core is being formed by the fusion of the adventicia 
of large central vessels, thus becoming a stem villus. In these larger villi a few central 
endothelial tubes (or early villous arteries and veins) have larger diameters, up to 100mm, 
and become surrounded by cells expressing alpha and gamma smooth muscles actins, 
vimentin and desmin. These contractile cells concentrate around the lumina, acquiring the 
full spectrum of cytoskeleton antigens. Following branching angiogenesis, non branching 
angiogenesis is observed from 24 weeks of gestation, due to the formation of mature 
intermediate villi, specialized in gas exchange. Those villi contain 1-2 long, poorly branched 
capillary loops, which coil and bulge through the trophoblastic surface, forming the 
terminal villi. These structures are the main site of diffusional gas exchange between the 
maternal and fetal circulations. This process includes decreased trophoblast proliferation 
and increased endothelial proliferation [Benirschke and Kaufmann, 1995]. 
As gestation increases, the terminal capillaries focally dilate and form large sinusoids, which 
counterbalance the effects of the long poorly branched capillaries on total fetoplacental 
vascular impedance. Increasing fetal blood pressure aids this dilation and fetoplacental blood 
flow rises throughout gestation to 40% of fetal cardiac output at term [Ahmed et al., 2000]. 
Pseudovasculogenesis is the process which remodelling of maternal uterine vessels occurs. 
Until 6 weeks post conception uterine arteries (spiral arteries) have high resistance and low 
capacity. After cytotrophoblast invasion they breakdown smooth muscle cells and replace 
maternal endothelial cells resulting to low resistance and high capacity vessels. Same 
process, but less extent occurs also in maternal veins. Pseudovasculogenesis is completed 
around 20 weeks of gestation. 
1.2 Fetal growth restriction 
Fetal growth restriction (FGR) is a complex condition in the field of current Obstetrics with 
an incidence rate of 4-7% of births and is associated with a 6- to 10-fold increased risk of 
perinatal morbidity and mortality [Jarvis et al., 2003]. FGR is not a disease entity with a 
unique pathophysiology. A variety of factors have been involved, including congenital 
abnormalities, drug abuse and infectious, immunological or anatomical factors. However, 
incomplete placentation (placental formation) is observed in most cases [Cetin et al., 2004]. 
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Two types of FGR have been described: early onset, that the growth restriction is 
symmetrical and late onset that restriction of growth is asymmetrical. The first one is more 
severe and usually has its underline cause in a specific defect that acts from the beginning of 
conception such as chromosomal anomalies, infections or substance abuse. Second and more 
common is less severe with smaller impact on the fetus and the causes may vary. Many 
elements can be of greater or lesser importance in the progress of this entity. Incomplete 
placentation and factors controlled by hypoxia are the most common pathophysiologic 
mechanism. 
A successful pregnancy outcome depends on the proper development of the fetoplacental 
vasculature in the villous core, which begins with the infiltration of cytotrophoblast in the 
endometrium and is completed in conjunction with the spiral arteries. It is widely accepted 
that shallow trophoblast invasion can lead to fetal hypoxia and impaired growth [Mayhew 
et al., 2004]. The proper and timely proliferation and differentiation of the villous 
cytotrophoblast stem cells, which are controlled by hypoxia, are crucial for adequate 
placentation [James et al., 2006]. Thus, the entire repertoire of hypoxia-associated growth 
factors is remarkably active during placental development. 
1.3 Fetal growth restriction and angiogenesis 
Angiogenesis is a placental factor playing an important role in the development of FGR. 
FGR occurs as a result of adequate vascular transformation and of terminal villous 
formation [Ahmed et al., 2000]. 
Based on the type of FGR (early or late onset) there are two models that may occur in the 
placental tissue. First is due to uteroplacental insufficiency and results to increased 
branching angiogenesis. Second and more common is due to placental failure and is 
accompanied by straight and unbranched capillaries, along with reduced cytotrophoblast 
proliferation, increased syncytial nuclei and erythrocyte congestion. All these suggest an 
increased rate of trophoblast proliferation. This situation has been interpreted as placental 
hyperoxia. Thus, fetoplacental blood flow is severely impaired and transplacental gas 
exchange is poor, placing the fetus at risk of hypoxia and acidosis [Macara et al., 1996]. 
Factors that are regulated by oxygen concentration are mainly important for the placental 
tissue to respond to hypoxic events. The most important known factors of this subgroup are 
hypoxia inducible factors (HIF). 
2. Hypoxia inducible factors 
Hypoxia Inducible Factors (HIF) are transcriptional factors that were discovered in 
mammalian cells under conditions of low oxygen, and appear to have a fundamental role in 
the cellular and systematic response to hypoxia, via the regulation of metabolism, cellular 
cycle, angiogenesis and apoptosis. HIFs are heterodimers constituted from the HIFa (1, 2 or 
3) and HIFb or ARNT. 
HIFa subunit is found in the cytoplasm and is transported in the nuclei in order to form HIF 
with the other subunit ARNT, which is expressed regularly in the nuclei, and achieve its 
transcriptional role. It has been found that transcriptional action of HIFa is achieved via 
bHLH (basic helix-loop-helix)-PAS domain in N-terminal. For this action the recruitment of 
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co-activators p300 and CBP is needed. While HIF-1 and HIF-2 have similar structure and 
action, it appears that HIF-3 presents suspensive action in the hypoxia, which has not 
however been confirmed [Kiichi et al., 2006]. 
HIFa under normoxic conditions is hydroxylated in two Prolyl domains (Pro 402 and Pro 
564) by their Prolyl Hydroxylation Domains (PHD-1,2 and 3), which induces the reaction 
with the von Hippel-Lindau (VHL) forming a dimmer that is proteosomical degradated. It 
appears that VHL is downregulated in hypoxia, consequently releasing the HIFa that at the 
same time is upregulated. PHD utilizes Ο2 as a substrate with a Km that is slightly above 
atmospheric concentration. The enzymatic activity is modulated by changes in Ο2 
concentration under physiological conditions. This regulation appears to be common for all 
three HIFa factors [Min et al., 2002]. 
Deductively, the HIFa factors are upregulated by hypoxia, while the ARNT is stably 
expressed and in order to they carry out their transcriptional role, they should form a 
heterodimmer in the nuclei. Under normal conditions, while HIFs continue to be expressed, 
VHL and PHD-1, 2 and 3 are upregulated in order to complete protesomical degradation of 
HIFs. The existing data for HIF-1a and HIF-2a show a regulating role in angiogenesis, 
metabolism, cellular cycle and apoptosis; for HIF-3a however there is still lack of evidence 
regarding his precise role [Makino et al., 2001]. On the contrary, factors PHD-1, 2 and 3 
appear to play all similar roles in the degradation of HIFa subunits [Salceda et al., 1997; 
Maxwell et al., 1999]. Important examples of factors that are regulated by HIF-1 are VEGF, 
PLGF, Flt-1 and Angiopoietin-2 regarding arterial destabilization and increased vascular 
permeability, MMPs, Angiopoietin-1, MCP-1 and PDGF regarding migration and 
proliferation of endothelial cells etc. Figure 1 represents the HIF pathway during normoxic 
and hypoxic conditions. 
2.1 Hypoxia inducible factors in placenta 
It is already known that one of the most important processes during gestation is the 
physiologic development of feto-placental unit that begins with the cytotrophoblast 
invasion in the endometrium and is completed with the creation of chorionic villi [Huppertz 
et al., 2007]. Initially the cytotrophoblast environment can be characterized as hypoxic, but 
after the completion of the conjunction with the spiral vessels there is a passage to 
physiologic oxygenation. During this process, structural changes are required for both the 
epithelium of endometrium and the endothelium and walls of the spiral arteries. The wall of 
vessels that is found to the side of fetus is replaced from trophoblasts. Cytotrophoblasts in 
this process turn from an expressive pattern of molecules of epithelial specification in an 
expressive pattern of adherence molecules that is more of endothelium cells differentiation. 
Many of these molecules are regulated by HIF. The cytotrophoblast tends to proliferate in 
hypoxia but to differentiate in physiological oxygenation, and these data show that 
cytotrophoblast activity depends on the presence of oxygen. 
Results from studies in animal models have shown that at the initial stages of pregnancy 
where PO2 is decreased, an increased action of regulating factors exists, mainly from HIF-1, 
HIF-2 and HIF-3. HIF-1 comprises a basic response of a cell to the hypoxic conditions. It is 
constituted by two subunits, HIF-1a and HIF-1b (ARNT). HIF-1a forms a heterodimmer 
with the HIF-1b and HIF-1, acts on the cell nucleus and regulates the expression of many 
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genes that play role in angiogenesis, cellular cycle and metabolism [Semenza et al., 2000]. 
Similar function appears also for the HIF-2, while for HIF-3 the existing data is insufficient. 
The regulation of these factors is depending on the partial pressure of oxygen, a fact that 
makes them immediately connected with hypoxic conditions in the feto-placental circulation 
such as preeclampsia or FGR [Smith et al., 2001]. 
 
Fig. 1. Graphical representation of the HIF pathway during normoxic and hypoxic 
conditions. In normoxia (grey arrows) PHD hydroxylates HIF-a, which then binds to vHL, 
leading to its proteosomal degradation. In hypoxia (black arrows) HIF-a enters the nucleus, 
forms a dimer with ARNT, which then binds to DNA, leading to gene transcription 
activation [Gourvas et al., 2010]. 
Regulation of HIFs appears to relate not only with the induction/suspension of their 
expression, but also with their degradation. Thus, in physiologic conditions the a- subunits 
of HIF are degradated with a mechanism that includes factors PHD-1, 2 and 3 (prolyl 
hydroxylation domain) and VHL. They are responsible for the hydroxylation and 
degradation of HIFa, so that HIFa cannot activate ARNT in the nuclei. In a second phase one 
more hydroxylation can contribute in the suspension of HIF, which becomes in asn803 and 
suspends the interaction with co-activators p300/CBP, which is essential for the induction of 
transcription [Lando et al., 2002]. 
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It is obvious that the regulation of HIF expression and function is achieved through a number 
of factors, such as PO2, VHL and PHD-1, 2 and 3. Consequently, a measurement of expression 
only of HIF in conditions with decreased supply of oxygen may lead to false conclusions, 
especially by considering that their regulation is also posttranscriptional through the action of 
PHD and VHL. Later during gestation, when fetal-placental unit provides satisfactory 
quantities of O2, HIFs are downregulated by decreased expression or degradation. In 
pathological situations, however, it is probable that this model is disturbed and the 
maintenance of decreased oxygenation affects the regulating action of these factors. Thus exists 
a change/imbalance in the expression of genes related with processes such as angiogenesis 
(VEGF, PLGF, PDGF, EPO, NOS2, FLT1 etc), metabolism (aldolase, hexokinase, pyrouvic 
kinase, lactic dehydrogonase etc) and cellular cycle (IGF, p21, p35srj etc). These changes may 
produce clinical signs and symptoms of FGR or preeclampsia or of both of them. 
3. Angiogenetic growth factors in FGR 
Numerous factors are thought to play a role in normal vascular adaptation to implantation. 
The VEGFs are specific stimulators of vascular permeability, as well as vascular endothelial 
cell protease production and migration, all of which are critical components of the 
angiogenic process [Folkman et al., 1987] Vascular endothelial growth factor also stimulate 
angiogenesis in a variety of in vivo and in vitro models [Klagsbrun et al., 1991]. The 
increased expression of VEGF-A, b-FGF, and eNOS that we have found in IUGR placentas 
may promote increased endothelial cell proliferation and migration and pathological 
angiogenesis [Kinzler et al., 2008]. 
VEGF, placental growth factor (PlGF), angiopoietins (Ang-1 and Ang-2) are involved not 
only in the regulation of vascular development and in remodeling during placentation, but 
also act as growth factors for driving growth and differentiation processes such as invasion. 
It has been hypothesized that an impairment of trophoblast invasion and a failure of spiral 
artery remodeling could have a role in the development of PE and FGR [Wulff et al., 2003]. 
Vascular endothelial growth factor-A (VEGF-A) and placental growth factor (PlGF) are 
probably the best-studied factors. VEGF interacts with VEGFR-1 (Flt-1) and VEGFR-2 (KDR) 
to promote endothelial cell proliferation, cell migration, and vascular permeability. PlGF 
shares biochemical and functional features with VEGF and interacts with VEGFR-1 (Flt-1). 
PlGF and VEGF-A have synergistic effects regarding angiogenesis, but vessels induced by 
PlGF are more mature and stable than vessels induced byVEGF-A [Chung et al., 2004]. PlGF 
is abundantly expressed in the human placenta. Both VEGF-A and PlGF may be important 
paracrine regulators of decidual angiogenesis and autocrine mediators of trophoblast 
function [Sherer et al., 2001]. 
A second family of growth factors, the angiopoietins, is also known for their regulating 
capacities regarding angiogenesis. Angiopoietin-1 (Ang-1) and angiopoietin-2 (Ang-2) bind 
with equal affinity to their receptor TIE-2, but have different functions. Ang-1 maintains vessel 
integrity and plays a role in the later stages of vascular remodeling [Geva et al., 2000]. Ang-2 is a 
functional antagonist of Ang-1 and leads to loosening of cell–cell interactions and allows access 
to angiogenic inducers like VEGF. Coexpression of VEGF and Ang-2 induces angiogenesis, but 
Ang-2 results in vascular regression in the absence of angiogenic signals. Ang-1 and Ang-2 have 
both been detected in decidual and placental tissues [Asahara et al., 1998]. 
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Various decidual cell types are capable of producing angiogenic factors. We recently 
showed the production of PlGF, KDR, Flt-1, Ang-2, and TIE-2 by endothelial cells and 
extravillous trophoblasts. Decidual stromal cells, glandular epithelium, and perivascular 
smooth muscle cells were found to produce all studied angiogenic factors [Plaisier et al., 
2007]. Uterine natural killer cells are also abundantly present in first-trimester decidua and 
are known to produce PlGF, VEGF, Ang-1, and Ang-2. 
4. Conclusion 
A successful pregnancy outcome depends on the proper development of the fetoplacental 
vasculature in the villous core, which begins with the infiltration of cytotrophoblast in the 
endometrium and is completed in conjunction with the spiral arteries. It is widely accepted 
that shallow trophoblast invasion can lead to fetal hypoxia and impaired growth. The 
proper and timely proliferation and differentiation of the villous cytotrophoblast stem cells, 
which are controlled by hypoxia, are crucial for adequate placentation and initiation of 
angiogenetic pathways. Numerous factors are thought to play a role in normal vascular 
adaptation to implantation. There is strong evidence that abnormal levels of angiogenic and 
antiangiogenic growth factors could in part be responsible for the pathophysiology 
associated with pregnancies complicated by FGR. 
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